Ocrelizumab for Multiple Sclerosis (CELLO Trial)

"This medical trial has specified an age range of 18 to 40 as the inclusion criteria. There are 417 trials that cater to patients younger than 18, and 1379 for individuals above 65 years old."

"Per the information found on clinicaltrials.gov, this trial is recruiting participants as previously reported. The first post was made in mid-February of 2022 with a subsequent update at the end of October."

"This clinical trial seeks 100 individuals between 18 and 40 years of age that have been diagnosed with multiple sclerosis. Specifically, applicants must meet the following criteria: be related to an individual who has clinically definite MS, possess established RIS diagnosis (CNS lesions consistent with McDonald 2017 criteria for DIS) within 5 years or known previous accumulation of CNS lesion in this time frame, no prior long-term immunomodulatory medication exposure, signed informed consent form, ability to comply with study protocol and provide written informed consent as well as present CNS lesions meeting McDonald 2017 criteria for DIS and serologic workup negating alternative diagnoses."

"This medical research is being conducted in a range of locations, including Icahn School of Medicine at Mount Sinai (New york), University of Utah (Salt Lake City) and Georgetown University (Washington D.C.). Additionally, there are 14 other trial sites involved."

"Through careful evaluation, our Power team has declared Ocrelizumab to be a 3 on the safety scale. This is because this therapy is already approved and in Phase 4 trials."

"Presently, 29 clinical investigations involving Ocrelizumab are in progress across 321 cities and 60 countries. This drug was initially trialled by Genentech Inc back in 2008 with 220 participants during its Phase 2 approval process. Subsequent studies have totaled 18340 to date."

"To execute the study, 100 suitable participants are needed. Genentech Inc., who is sponsoring this trial, will be conducting it in various sites such as Icahn School of Medicine at Mount Sinai (New york City) and University of Utah (Salt Lake City)."

"Ocrelizumab was initially studied in 2008 at CHU De Nimes, Hopital Caremeau; Service De Neurologie Du Prof. Pierre Labauge and has since been the subject of 18340 completed clinical trials. Currently, there are 29 active trials taking place across various locations with a high concentration being conducted out of New york City."